TY - CHAP M1 - Book, Section TI - Gastric Adenocarcinoma A1 - Ursem, Carling A1 - McQuaid, Kenneth R. A2 - Papadakis, Maxine A. A2 - McPhee, Stephen J. A2 - Rabow, Michael W. A2 - McQuaid, Kenneth R. Y1 - 2023 N1 - T2 - Current Medical Diagnosis & Treatment 2023 AB - Key Clinical Updates in Gastric AdenocarcinomaTriplet chemotherapy for resectable gastric cancer is recommended for patients who are fit but is associated with more toxicity than doublet chemotherapy.The development of immunotherapy represents a promising strategy in a selected patients with locally advanced and metastatic gastric cancer. Testing for microsatellite instability-high (MSI-H), mismatch repair deficiency (dMMR), PD-1, and PD-L1 is recommended in advanced disease to identify tumors that may respond to immunotherapy.ASGE Standards of Practice Committee; Jue TL et al. Gastrointest Endosc. [PMID: 33168194]de Steur WO et al; CRITICS investigators. Ann Oncol. [PMID: 33227408]Kawazoe A et al. Jpn J Clin Oncol. [PMID: 33241322]Ng SP et al. Ann Surg Oncol. [PMID: 33689079] SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - accessmedicine.mhmedical.com/content.aspx?aid=1193162330 ER -